Skip to Main Content

KMAP BULLETIN: Preferred Drug List Update

Date: 09/10/19

KMAP GENERAL BULLETIN 19149 (PDF)

There is a Preferred Drug List (PDL) update effective September 1, 2019. Reference the Preferred Drug List (PDL) page on the Kansas Department of Health and Environment (KDHE) website.

The following medications are nonpreferred and require prior authorization:

  • Dupilumab (Dupixent®)
  • Infliximab (Inflectra)
  • Infliximab (Renflexis)
  • Mepolizumab (Nucala®)
  • Reslizumab (Cinqair®)
  • Sevelamer Carbonate (Renvela®) Powder Pack

The following medications have been moved to a preferred status and no longer require PDL prior authorization:

  • Olmesartan (Benicar®)
  • Olmesartan/HCTZ (Benicar HCT®)
  • Sevelamer Carbonate (Renvela®) Tablet
  • Sevelamer HCl (Renagel®) Tablet
  • Spinosad (Natroba®) (BRAND only)

Note: The effective date of the policy is September 1, 2019.

The implementation of State policy by the KanCare managed care organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The KanCare Open Claims Resolution Log on the KMAP Bulletins page documents the MCO system status for policy implementation and any associated reprocessing completion dates, once the policy is implemented.